Graft-versus-host disease (GVHD) is a major complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT) that is frequently associated with bone marrow (BM) suppression, and clinical management is challenging. BM endothelial progenitor cells (EPCs) play crucial roles in the regulation of haematopoiesis and thrombopoiesis. However, little is known regarding the functional roles of BM EPCs in acute GVHD (aGVHD) patients. In the current prospective case-control study, reduced and dysfunctional BM EPCs, characterized by decreased migration and angiogenesis capacities and increased levels of reactive oxygen species (ROS) and apoptosis, were found in aGVHD patients compared with those without aGVHD. Moreover, lower frequency and increased levels of ROS, apoptosis and DNA damage, but reduced colony-forming unit-plating efficiency were found in BM CD34 + cells of aGVHD patients compared with those without aGVHD. The severity of aGVHD and GVHD-mediated cytopenia was associated with BM EPC impairment in aGVHD patients. In addition, the EPC impairment positively correlated with ROS level. Taken together, our results suggest that reduced and dysfunctional BM EPCs may be involved in the pathogenesis of aGVHD. Although these findings require validation, our data indicate that improvement of BM EPCs may represent a promising therapeutic approach for aGVHD patients.
aGVHD (Svahn et al, 2002 (Svahn et al, , 2005 Lee et al, 2004; Pulanic et al, 2009; Mensen et al, 2014) , suggesting that the BM might be a target of aGVHD (Shono et al, 2010; von Bonin & Bornhauser, 2014; Yao et al, 2014) . Murine studies have provided evidence of BM GVHD and identified osteoblasts and sinusoidal endothelial cells as the targets of GVHD in the BM microenvironment (Shono et al, 2010; Yao et al, 2014) . However, it is largely unknown whether BM endothelial progenitor cells (EPCs) are impaired in GVHD patients. Moreover, the in-depth mechanisms of the GVHD-associated haematopoietic dysfunction remain to be elucidated, and the clinical management is challenging.
The pathogenesis of aGVHD is commonly considered to be immune-mediated (Okamoto et al, 1991; Chao & Chen, 2006; Ferrara & Reddy, 2006; Sun et al, 2007; Petersdorf, 2013; Filippini & Rutella, 2014; Markey et al, 2014; Teshima et al, 2016) . Corticosteroids are the standard first-line therapy, achieving responses in approximately 25-40% of aGVHD patients, with clinically relevant improvement, defined as regression of skin rash or decrease in the volume of diarrhea and the extent of liver function abnormalities, in 40-50% of patients with grade II to IV aGVHD (Deeg, 2007) . However, for severe aGVHD patients who exhibit no response to corticosteroid, the pathogenesis remains poorly understood, and the clinical prognosis after treatment with the available second-line therapies, which aim at inactivation of alloreactive donor T lymphocytes or Natural Killer cells, host antigen-presenting cells and cytokines, among other targets, is poor (Chao & Chen, 2006; Bacigalupo, 2007) . These reports indicate that immune-mediated injury may not be the sole pathogenic mechanism of aGVHD. Consequently, it is imperative to identify novel therapeutic targets based on the pathogenesis of GVHD to improve the prognosis of GVHD patients.
GVHD is also associated with injury of circulating endothelial cells (ECs), which determines the severity of GVHD (Tichelli & Gratwohl, 2008) . ECs are one of the important targets for alloreactive donor cytotoxic T lymphocytes in patients with aGVHD (Dumler et al, 1989; Biedermann et al, 2002) . Murine studies suggest that EPCs are key cells that support haematopoiesis and thrombopoiesis in the BM microenvironment Morrison & Scadden, 2014) . In this regard, EPCs improved the quality and quantity of transplanted haematopoietic stem cells (HSCs) in mice (Qiao et al, 2017) . More recently, we reported that impaired BM EPCs contribute to the occurrence of poor graft function (PGF) and prolonged isolated thrombocytopenia (PT) after allo-HSCT in humans (Kong et al, 2013 (Kong et al, , 2016a (Kong et al, , 2018a Shi et al, 2016) . We further found that disruption of the BM EPCs may hamper the differentiation progress from HSCs to megakaryocytes, resulting in the occurrence of corticosteroid-resistant immune thrombocytopenia (ITP), indicating that immune-mediated platelet destruction is not the sole pathogenic mechanism of corticosteroid-resistant ITP (Kong et al, 2018b) . Nevertheless, no previous studies have focused on the number and functional role of BM EPCs and HSCs in aGVHD patients after allo-HSCT. Therefore, the current study was performed to evaluate whether the quantity and function of BM EPCs and HSCs in patients with aGVHD differed from those without aGVHD and to explore whether the severity of aGVHD and GVHDmediated cytopenia was associated with impaired BM EPCs and HSCs in aGVHD patients. Our aim was to provide new insights into the pathogenesis underlying aGVHD after allo-HSCT.
Methods

Patients and controls
In this prospective case-control study, cases were identified from patients who received an allotransplant between 1 March 2017 and 25 October 2017 at Peking University Institute of Haematology. A total of 41 patients with aGVHD after allo-HSCT were eligible. Acute GVHD patients underwent BM analyses at 1, 2 or 3 months after allo-HSCT. For each case, 2 matched transplant recipients without aGVHD (non-aGVHD; N = 82) were selected at random from the same cohort after matching for age at HSCT (AE1 year), disease status at allo-HSCT and time of BM microenvironment evaluation after allo-HSCT (AE5 days) ('risk-set sampling') (Wacholder et al, 1992) . Patients with evidence of severe infection or haematological relapse at BM microenvironment evaluation, were excluded. The characteristics of the patients with aGVHD and without aGVHD controls are summarized in Table I. BM samples from 15 age-and gender-matched healthy donors for allo-HSCT were used as healthy controls. The healthy control group comprised 8 males and 7 females, ranging in age from 18 to 55 years (median, 32 years).
The study was approved by the Ethics Committee of Peking University People's Hospital, and written informed consent was obtained from all patients, in compliance with the Declaration of Helsinki.
Clinical definitions
Acute GVHD was diagnosed and graded based on clinical symptoms and/or skin, oral mucosa, liver or gut biopsy, and disease severity was scored using published consensus criteria (Przeiorka et al, 1995; Cahn et al, 2005; Ferrara et al, 2009) . Depending on the time of occurrence, GVHD has traditionally been classified into aGVHD, which occurs within the first 100 days after HSCT, and chronic GVHD (cGVHD), which occurs after day 100 (Ferrara & Deeg, 1991; Ferrara & Reddy, 2006; Deeg, 2007; Sun et al, 2007) . The severity of aGVHD is ascertained by the extent of involvement of the three main target organs and assigned an overall grade of I-IV (Przeiorka et al, 1995; Cahn et al, 2005; Ferrara et al, 2009) . aGVHD-associated cytopenia was defined as aGVHD patients with hypo-or aplastic BM with the following: (i) an absolute neutrophil count (ANC) ≤0Á5 9 10 9 /l; and/or (ii) a platelet count ≤20 9 10 9 /l; and/or (iii) a haemoglobin concentration ≤70 g/l for at least three consecutive days within 100 days of HSCT or in accordance with a requirement for platelet and/or red blood cell transfusion and/or granulocyte colony-stimulating factor support. Patients with evidence of severe infection or haematological relapse after allo-HSCT were excluded.
Isolation, cultivation, and characterization of primary BM EPCs BM samples were obtained from patients with aGVHD (N = 41) or without aGVHD (N = 82) and healthy donors *Group matching criteria included age at HSCT (AE1 year), pre-HSCT cycles of chemotherapy (AE1 cycle), disease status at HSCT and BM microenvironment evaluated time after HSCT (AE5 days). For each case, two non-aGVHD control was randomly selected from the same cohort in which the aGVHD occurred ('risk-set sampling'). †The continuous variables were compared using the Mann-Whitney U-test, and the differences in frequency between the 2 groups were compared using the chi-square test. The criterion for statistical significance was P < 0Á05. Abbreviations: allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; aGVHD, acute graft-versus-host disease; BM, bone marrow; PB, peripheral blood; WBC, white blood cell; ANC, absolute neutrophil cell; Hb, hemoglobin; PLT, platelet; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; HLA, human leukocyte antigen; CMV, cytomegalovirus.
(N = 15). Peripheral blood (PB) samples were obtained AE2 days of BM sampling. BM mononuclear cells (BMMNCs) were isolated by density gradient centrifugation with lymphocyte separation medium (GE Healthcare, Milwaukee, WI, USA). As previously reported (Shi et al, 2016; Kong et al, 2018b) , BMMNCs (1 9 10 6 /well) were cultivated with EGM-2-MV-SingleQuots (Lonza, Walkersville, MD, USA) and 10% fetal bovine serum (Gibco, MA, Rockville, USA) at 37°C in a humidified incubator with 5% CO 2 for 7 days before use in experiments in 24-well culture plates (Corning Incorporated, Corning, NY, USA), which were pre-coated with fibronectin (Sigma, St. Louis, MO, USA). As previously described (Gehling et al, 2000; Peichev et al, 2000; Kuwana et al, 2004; Parham et al, 2014; Shi et al, 2016; Kong et al, 2018b) , primary pre-cultivated and 7-daycultivated BM EPCs were confirmed by the positive staining with the following monoclonal antibodies: mouse antihuman CD34, vascular endothelial growth factor receptor 2 (VEGFR2, CD309), and CD133 monoclonal antibodies (Becton Dickinson Biosciences, San Jose, CA, USA). Samples were then evaluated using a BD LSRFortessa cell analyser (Becton Dickinson) and the data were analysed using BD LSRFortessa software (Becton Dickinson).
DiI-Ac-LDL uptake and FITC-UEA-1-binding assay DiI-acetylated low-density lipoprotein (DiI-Ac-LDL, Life Technologies, Gaithersburg, MD, USA) was incubated at 10 lg/ml with 7-day cultivated adherent cells at 37°C for 4 h. The cells were then washed and fixed in 4% pre-chilled paraformaldehyde for 10 min. After fixing, the cells were incubated for 1 h with 10 lg/ml fluorescein isothiocyanate (FITC)-labelled Ulex europaeus agglutinin-I (FITC-UEA-I, Sigma) at room temperature. To evaluate the number of double-positive-stained EPCs per well, three random power fields were counted using a fluorescence microscope (Olympus, Tokyo, Japan).
Cell counting
The adherent BM EPCs at day 7 of cultivation were washed with phosphate-buffered saline (PBS) and gently detached with trypsin containing 0Á25% EDTA. The number of living cells per well was counted with trypan blue (Solarbio, Beijing, China) by independent blinded investigators.
Cell proliferation assay
Cell proliferation was measured using a Cell Counting kit-8 (CCK-8) (Dojido, Kumamoto, Japan) assay according to the manufacturer's instructions. The final absorbance of each well was determined at 450 nmol/l using a microplate reader (Bio-Rad, Foster City, CA, USA).
Migration assay
Cell migration was assayed using a Transwell chamber (Corning). The cells were trypsinised and seeded in the upper chamber at a density of 5 9 10 4 cells per well, while 500 ll of medium was added to the lower chamber. The cells were cultured for 24 h, and migrated cells were fixed with paraformaldehyde for 30 min. Cells on the bottom surface of the membrane were then stained with crystal violet for 20 min. Cell images were obtained under a phase-contrast microscope (Olympus), and cells were counted manually in 3 random fields/sample.
Tube-formation assay
The plate and pipette tips used were pre-chilled, and each well was pre-coated with cold Matrigel (Corning). A total of 5 9 10 4 EPCs at day 7 of cultivation were transferred to the 
Apoptosis analysis
To detect apoptosis, cells stained with the aforementioned EPC markers were incubated with Annexin-V and 7-aminoactinomycin D (7-AAD) from an Apoptosis Detection Kit (Becton Dickinson) according to the manufacturer's instructions.
Measurement of intracellular reactive oxygen species (ROS) levels
The aforementioned EPC marker-stained cells were incubated with 10 lmol/l 2 0 ,7 0 -dichlorofluorescence diacetate (DCFH-DA, Beyotime, Beijing, China) at 37°C for 20 min. The mean fluorescence intensity of intracellular ROS was measured on a BD LSRFortessa cell analyser (Becton Dickinson) (Shi et al, 2016) .
Immunofluorescent staining
BM trephine biopsies (BMBs) were obtained from the posterior superior iliac spine of the patients with or without aGVHD and healthy donors. As previously described (Duan et al, 2014; Kong et al, 2018a,b) , the immunofluorescence staining of EPCs in the BMBs were performed with the mouse anti-human CD34 (Becton Dickinson) and rabbit anti-human CD133 (Abcam, Cambridge, MA, USA) antibodies. The goat anti-rabbit 555 and donkey anti-mouse 488 (Invitrogen, Carlsbad, CA, USA) antibodies were added at RT for 1 h. 4 0 ,6-Diamidino-2-phenylindole (DAPI) was Single-cell gel electrophoresis (the comet assay)
Sorted CD34 + BMMNCs were suspended in low melting point agarose in PBS, and immediately pipetted onto a frosted glass microscope slide, which had been pre-coated with melting point agarose similarly prepared in PBS as described previously (Kong et al, 2016b) . One hundred comets of each slide were captured using fluorescence microscope, and analysed with CASP1.2.3 software (Institute of Theoretical Physics, University of Wroclaw, Wroclaw, Poland).
Colony-forming unit (CFU) assays
CFUs were assayed using MethoCult TM H4434 Classic (Stem Cell Technologies, Vancouver, BC, Canada) as described previously (Kong et al, 2016b (Kong et al, , 2018b Shi et al, 2016) . 2 9 10 3 CD34 + cells were plated in 24-well plates and cultured for 14 days. Colony-forming unit erythroid (CFU-E), burstforming unit erythroid (BFU-E), colony-forming unitgranulocyte-macrophage (CFU-GM) and colony-forming unit-granulocyte, erythroid, macrophage and megakaryocyte (CFU-GEMM) measurements were evaluated using an inverted light microscope. Cultures were assayed in duplicate, and the results are expressed as the mean AE standard error of the mean (SEM).
Statistical analyses
Statistical analyses were performed using one-way analysis of variance (ANOVA) for comparisons between groups. Subject variables were compared using a chi-squared test for categorical variables and a Mann-Whitney U test for continuous variables. Analyses were performed with GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA), and P-values <0Á05 were considered significant.
Results
Patient characteristics
As shown in Table I , most of the demographic and clinical characteristics, including age, gender, underlying disease, status at HSCT, number and source of stem cells, donor match, gender mismatch, ABO mismatch, pre-HSCT cycles of chemotherapy, conditioning, post-transplant interval, history of cytomegalovirus (CMV) reactivation or ganciclovir treatment, were not significantly different between patients with and without aGVHD. The white blood cell (WBC) count, ANC, platelet count and haemoglobin levels were significantly different between patients with and without aGVHD.
Impairment of BM EPCs in aGVHD patients
The representative EPCs phenotype was characterized by demonstrating the positive expression of CD34, CD309 and CD133 by flow cytometry ( Fig 1A) . As illustrated in Fig 1B- D, the percentages, intracellular ROS levels and apoptosis rates of primary BM EPCs were compared between patients with onset of aGVHD and those without aGVHD. The baseline percentage of BM EPCs (Fig 1B; 0Á04-% AE 0Á004% vs. 0Á13% AE 0Á02%; P < 0Á0001) from patients with aGVHD was significantly lower than that of patients without aGVHD, whereas the ROS level (Fig 1C; 2617 AE 265Á7 vs. 1415 AE 94Á47; P < 0Á0001) and apoptosis rate (Fig 1D; 44Á74% AE 3Á38% vs. 30Á75% AE 2Á96%; P = 0Á006) of BM EPCs from patients with aGVHD were significantly higher than those of patients without aGVHD.
Significant impairment of BM EPCs was observed in patients with aGVHD > grade II
To evaluate whether the severity of aGVHD was associated with the degree of BM EPC or PB EC impairment, the percentages of cell types, intracellular ROS levels and apoptosis rates were compared between patients with aGVHD > grade II (N = 11) and aGVHD ≤grade II (N = 30). The frequency of BM EPCs (Fig 1E; 0Á02% AE 0Á004% vs. 0Á05% AE 0Á005%; P = 0Á0002) in patients with onset of aGVHD > grade II was significantly lower than in those with aGVHD ≤ grade II. By contrast, the ROS level (Fig 1F; 4444 AE 594Á1vs. 1947 AE 175Á4; P < 0Á0001) and apoptosis rate (Fig 1G; 57Á73% AE 6Á12% vs. 37Á43% AE 2Á71%; P = 0Á008) of BM EPCs from patients with onset of aGVHD > grade II were markedly higher than those of patients with aGVHD ≤ grade II.
Increased number and ROS level and apoptosis of PB ECs in aGVHD patients
The percentages, numbers, intracellular ROS levels and apoptosis rates of primary PB ECs were compared between patients with onset of aGVHD and those without aGVHD (Fig 2A-D) .
The baseline percentage (Fig 2A; 0Á29% AE 0Á06% vs. 0Á15-% AE 0Á02%; P = 0Á0009), number (Fig 2B; [14Á53 AE 3Á07] 9 10 3 /ml vs. [8Á20 AE 1Á32] 9 10 3 /ml; P = 0Á001), ROS level ( Fig 2C; 2570 AE 306Á4 vs. 1377 AE 106Á3; P < 0Á0001) and apoptosis rate (Fig 2D; 49Á12% AE 3Á52% vs. 37Á9% AE 2Á31%; P = 0Á01) of PB ECs from patients with aGVHD were significantly higher than those without aGVHD.
Significant impairment of PB ECs was observed in patients with aGVHD > grade II
To evaluate whether the severity of aGVHD was associated with the degree of PB EC impairment, the percentages of cell types, intracellular ROS levels and apoptosis rates were compared between patients with aGVHD >grade II and aGVHD ≤grade II. The frequency (Fig 2E; 0.62%±0.2% vs. 0.16%±0.03%; P < 0Á0001), number [ Fig 2F; (31Á7 AE 9Á35) 9 10 3 /ml vs. (8Á21 AE 1Á27) 9 10 3 /ml; P = 0Á001], ROS level (Fig 2G; 3935 AE 858Á1 vs. 2069 AE 227Á2; P = 0Á02), and apoptosis rate of PB ECs (Fig 2H; 67Á82% AE 5Á96% vs.42Á26% AE 3Á57%; P = 0Á001) from patients with onset of aGVHD >grade II were significantly higher than those of patients with aGVHD ≤ grade II.
Reduced and dysfunctional BM EPCs from patients with aGVHD
As shown in Fig 3, in situ To evaluate the quantity and function of the BM EPCs, cell count, double-positive staining with DiI-AcLDL and FITC-UEA-1, and angiogenic potential (including migration and tube formation) were analysed at day 7 of cultivation. Human BM EPCs were characterized as spindle-shaped and elongated adherent cells that were capable of DiIAcLDL uptake and FITC-UEA-I binding (Fig 4A) . Doublepositive-stained BM EPCs were significantly rarer in patients with aGVHD than in those without GVHD (Fig 4A; 45Á67 AE 4Á94 vs. 81Á11 AE 7Á45; P = 0Á003). Moreover, BM EPCs >from aGVHD patients showed significantly reduced tube formation (Fig 4B; 1069 AE 154Á2 vs. 2188 AE 260Á7; P = 0Á008) and migration (Fig 4C; 37Á56 AE 7Á51 vs. 80 AE 9Á14; P = 0Á001).
Reduced and dysfunctional CD34 + cells in aGVHD patients
To evaluate the quantity and function of primary CD34 + cells, the percentage, intracellular ROS level and apoptosis rate of CD34 + cells were compared between patients with onset of aGVHD and those without aGVHD (Fig 5) . The percentage of BM CD34 + cells (Fig 5A; 0Á25% AE 0Á04% vs.
0Á81% AE 0Á1%; P < 0Á0001) from patients with aGVHD was significantly lower than from patients without aGVHD, whereas ROS level ( Fig 5B; 7331 AE 625Á9 vs. 4360 AE 216Á6; P < 0Á0001) and apoptosis rate of CD34 + cells (Fig 5C; 54Á22% AE 5Á15% vs. 39Á06% AE 3Á52%; P = 0Á03) from patients with aGVHD were significantly higher than those of CD34 + cells from non-aGVHD patients.
The percentage of PB CD34 + cells (Fig 5D; 0Á38% AE 0Á06% vs. 0Á56% AE 0Á08%; P = 0Á02) from patients with aGVHD was significantly lower than from patients without aGVHD, whereas the ROS level (Fig 5E; 5240 AE 609Á1 vs. 3133 AE 177Á4; P = 0Á002) and apoptosis rate of CD34 + cells (Fig 5F; 78Á58% AE 3Á02% vs. 57Á84% AE 3Á4%; P = 0Á0004) from patients with aGVHD were significantly higher than those of CD34 + cells from patients without aGVHD.
Significant impairment of CD34 + cells in patients with aGVHD > grade II
To evaluate whether the severity of aGVHD was associated with the degree of CD34 + cells impairment, the percentage, intracellular ROS level and apoptosis rate of CD34 + cells were (Fig 5G; 0Á11% AE 0Á03% vs.0Á3% AE 0Á04%; P = 0Á009). By contrast, the ROS level (Fig 5H; 12373 AE 1131 vs. 5483 AE 371; P < 0Á0001) and + cells from patients with aGVHD, non-GVHD and normal controls. Continuous variables were compared using Mann-Whitney U test. All P-values <0Á05 were considered significant and are provided in the figure. (a) GVHD, (acute) graft-versus-host disease; BFU-E, burst-forming unit erythroid; BM, bone marrow; BMMNC, bone marrow mononuclear cell; CFU, colony-forming unit; CFU-E, colony-forming unit erythroid; CFU-GEMM, colony-forming unit-granulocyte, erythroid, macrophage and megakaryocyte; EPC, endothelial progenitor cell; GFU-GM, colony-forming unit-granulocyte-macrophage; GVHD-NP, acute graft-versus-host disease without cytopenia; GVHD-P, acute graft-versus-host disease with cytopenia; MFI, mean fluorescence intensity; ROS, reactive oxygen species.
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[Colour figure can be viewed at wileyonlinelibrary.com] Fig 7. The impairment of EPCs was associated with the severity of cytopenia in allo-transplanted patients. Correlations between the percentage of EPCs in BM or the intracellular ROS level of EPCs from BM and blood cell counts were analysed in allo-transplanted patients (aGVHD and non-GVHD patients). Decreased BM EPCs were associated with (A) thrombocytopenia, (B) leucopenia, (C) neutropenia, and (D) hypohaemoglobinaemia in allo-transplanted patients. In addition, increased intracellular ROS levels in EPCs from the BM were associated with (E) thrombocytopenia, (F) leukopenia, (G) neutropenia, and (H) hypohaemoglobinemia in allo-transplanted patients. Continuous variables were compared using Mann-Whitney U test. All P-values <0Á05 were considered significant and are provided in the figure. (a)GVHD, (acute) graftversus-host disease; ANC, absolute neutrophil count; BM, bone marrow; BMMNC, bone marrow mononuclear cell; EPC, endothelial progenitor cell; Hb: haemoglobin; ROS, reactive oxygen species. apoptosis rate of BM CD34 + cells (Fig 5I; 73Á36% AE 9Á11% vs.
43Á45% AE 4Á47%; P = 0Á006) from patients with onset of aGVHD > grade II were markedly higher than those of BM CD34 + cells from aGVHD ≤grade II patients. In addition, the ROS level (Fig 5K; 9215 AE 1634 vs. 3783 AE 297Á5; P < 0Á0001) and apoptosis rate of PB CD34 + cells (Fig 5L; 92Á37% AE 1Á17% vs. 73Á52% AE 3Á7%; P = 0Á002) in patients with the onset of aGVHD > grade II were markedly higher than those with aGVHD ≤ grade II, whereas the percentage of PB CD34 + cells (Fig 5J; 0Á37-% AE 0Á09% vs. 0Á38% AE 0Á07%; P > 0Á99) was not significantly different between the two groups.
Impairment of BM EPCs and CD34 + cells in patients with aGVHD-associated cytopenia
To evaluate whether aGVHD-associated cytopenia was correlated with the impairment of primary BM EPCs and CD34 + cells, the percentages, intracellular ROS levels and apoptosis rates of BM EPCs and CD34 + cells were compared between aGVHD patients with cytopenia and patients without cytopenia. The frequencies of BM EPCs (Fig 6A; 0Á02% AE 0Á009% vs. 0Á05% AE 0Á004%; P < 0Á0001) and CD34 + cells (Fig 6D; 0Á1% AE 0Á07% vs. 0Á29% AE 0Á04%; P = 0Á0003) in aGVHD patients with cytopenia were significantly lower than those in patients without cytopenia. By contrast, the ROS levels in BM EPCs (Fig 6B; 4834 AE 728Á6 vs. 2039 AE 164Á7; P = 0Á0001) and CD34 + cells (Fig 6E; 12214 AE 1630 vs.
5958 AE 421Á4; P = 0Á0001) in aGVHD patients with cytopenia were markedly higher than those in patients without cytopenia, as were the apoptosis rates in BM EPCs (Fig 6C; 59Á49% AE 5Á59% vs. 39Á01% AE 3Á34%; P = 0Á006) and CD34 + cells (Fig 6F; 72Á2% AE 10Á16% vs. 47Á22% AE 5Á25%; P = 0Á03).
DNA damage and reduced colony-forming unit-plating efficiency of BM CD34 + cells in aGVHD patients
The Comet assay was performed to evaluate the DNA damage of BM CD34 + cells. As shown in Fig 6G, the BM CD34 + cells from normal controls were round-shaped without tails. By contrast, the BM CD34 + cells from patients with aGVHD showed longer tails than those without aGVHD. Moreover, both the frequencies of comet cells and tail DNA in BM CD34 + cells of patients with aGVHD were significantly higher than those without aGVHD and normal controls. BM CD34 + cells from patients with aGVHD had significantly lower plating efficiencies (Fig 6H) for all type of haematopoietic progenitors, including CFU-E (17 AE 1 vs. 33 AE 9; P = 0Á03), BFU-E (15 AE 2 vs. 28 AE 7; P = 0Á02), CFU-GM (13 AE 2 vs. 28 AE 3; P = 0Á006) and CFU-GEMM (1 AE 0Á3 vs. 3 AE 0Á3; P = 0Á007), compared to patients without aGVHD. The CFU plating efficiencies of the patients with aGVHD were lower than those of normal controls (CFU-E 17 AE 1 vs. 45 AE 5; P = 0Á0007; BFU-E 15 AE 2 vs. 34 AE 5; P = 0Á007; CFU-GM 13 AE 2 vs. 28 AE 3; P = 0Á001; and CFU-GEMM 1 AE 0Á3 vs. 4 AE 1; P = 0Á001).
Cytopenia was significantly correlated with impairment of BM EPCs in patients after allo-HSCT
The correlations between blood cell counts and the percentages and intracellular ROS levels of BM EPCs were analysed in patients after allo- 
The impairment of EPCs, ECs and CD34
+ cells was correlated with the elevated ROS level in patients with aGVHD
In order to compare the BM and paired PB in the same aGVHD patient, the EPCs and CD34 + cells in BM and ECs and CD34 + cells in PB were analysed in aGVHD patients.
The percentage of PB ECs ( Figure S1A left; 0Á18% AE 0Á02% vs. 0Á06% AE 0Á01%; P < 0Á0001) was significantly higher than that of BM EPCs in the same patients with aGVHD, whereas the percentage ( Figure S1B left; 0Á24% AE 0Á02% vs. 0Á48% AE 0Á06%; P = 0Á0003) and ROS level in PB CD34 + cells ( Figure S1D left; 4548 AE 541 vs. 6730 AE 763Á7; P = 0Á002) were significantly lower than those in BM CD34 
Discussion
The current study is the first to demonstrate reduced and dysfunctional BM HSCs and EPCs, characterized by decreased migration and angiogenesis capacities and increased apoptosis, in aGVHD patients after allo-HSCT. Moreover, the impairment of EPCs was associated with elevated intracellular ROS levels in aGVHD patients. Furthermore, the severity of aGVHD or GVHD-mediated cytopenia was associated with the BM EPC and HSC impairment in aGVHD patients after allo-HSCT. Our data indicate that reduced and dysfunctional BM EPCs may be involved in the pathogenesis of aGVHD after allo-HSCT. As a preferential element of the BM microenvironment, EPCs can support haematopoiesis, endothelial tissue repair and neovasculogenesis Matthews & Ross, 2015) . Emerging clinical and physiopathological evidence suggests that the vascular endothelium has already been attacked by aGVHD in the early phase, and the increased circulating ECs represent a surrogate marker of endothelial damage (Woywodt et al, 2004; Biedermann, 2008) . Medinger et al (2016) reported that the number of circulating ECs in PB is increased in patients with aGVHD compared to those without aGVHD, which is consistent with our findings. Nevertheless, there are some discrepancies about the effect of BM vascular microenvironment on GVHD. Penack et al (2010) found increased neovascularization in GVHD target tissues, such as liver and intestines, in a murine GVHD model. Administration of anti-vascular endothelial-cadherin antibody inhibited neovascularization by donor BM-derived cells without affecting host vascularization, inhibited both GVHD and tumor growth, and increased survival. By contrast, Yao et al (2014) , reported that the vascular niche is a target of GVHD in a histocompatibility complex-haploidentical matched murine transplant model. In HSCT recipient mice, infusion of EPCs efficiently repaired damaged vascular endothelium and promoted haematopoietic and immune reconstitution, which can also ameliorate aGVHD (Zeng et al, 2012) . Several reasons may account for the inconsistent findings about the effect of EPCs on GVHD, such as the different subjects and EPCs phenotypes utilized for analyses in the studies. Emerging evidence from murine studies suggests that BM EPCs are the precursors of circulating ECs (Carmeliet, 2000; Bautch, 2011) . Upon vascular injury, EPCs are mobilized from BM into PB and home to the sites of damaged vasculature, where they are incorporated into the growing vasculature through differentiation into ECs, supporting their important roles in regulation of neovascularization, tissue regeneration and vascular repair (Zampetaki et al, 2008; George et al, 2011; Qiao et al, 2017) Consistent with the findings in BM of aGVHD mice (Yao et al, 2014) and in PB of aGVHD patients (Medinger et al, 2016) , the current study found reduced and dysfunctional BM EPCs, whereas PB ECs were increased, in aGVHD patients, especially in grade III to IV aGVHD patients. Based on previous reports (Carmeliet, 2000; Zampetaki et al, 2008; Bautch, 2011; George et al, 2011; Qiao et al, 2017) and the current study, it is plausible that EPCs in different circumstances may have different reactive mechanisms, and further functional studies are needed to clarify the discrepancy of the number of EPCs between BM and PB in aGVHD patients.
GVHD-associated haematopoietic dysfunction is a lifethreatening complication after allo-HSCT. Prompt and stable haematopoietic reconstitution after allo-HSCT depends on both HSCs and the BM microenvironment. Murine studies showed that endosteal cells, EPCs and perivascular cells are the key components of the BM microenvironment, and they provide crucial signals that regulate the self-renewal, differentiation, and quiescence of HSCs (Zhang et al, 2003; Ding et al, 2012) . Using a murine major histocompatibility complex-mismatched transplant model, Shono et al (2010) found that impaired haematopoiesis, which especially affected B cell lineages, is not caused by direct damage to CD34 + cells in GVHD but is instead caused by GVHD-targeted impaired osteoblasts in the BM endosteal niche, consequently leading to haematopoietic dysfunction. von Bonin and Bornhauser (2014) reported that GVHD-mediated lymphoid or nonlymphoid cytopenia might be induced both by a disturbance in HSC maturation and consumption of already mature haematopoietic cells. Consistent with the defective BM EPCs and HSCs in PGF patients post allo-HSCT (Kong et al, 2016b; Shi et al, 2016) , we provide experimental evidence that BM EPCs and HSCs are quantitatively and functionally impaired, and significantly correlated with cytopenia in aGVHD patients. Moreover, we observed the different degree of impairment of BM EPCs and HSCs in non-aGVHD patients compared with healthy controls, which might be attributed to the conditioning regimens of allo-HSCT, engraftment of donor cells, CMV infection and drugs (Simmons et al, 1990; Almeida et al, 1994; Steffens et al, 1998; Wang et al, 2013; Lai et al, 2014) . Considering the predominant role of EPCs in supporting HSCs in the BM microenvironment (Rafii et al, 1995; Psaila et al, 2012) and the current data, it is conceivable that immune-mediated BM EPC impairment may hamper the HSC differentiation progress, resulting in the occurrence of aGVHD-associated cytopenia after allo-HSCT. However, we are aware that the pathogenesis of aGVHD-associated cytopenia is heterogeneous. Further functional studies with large-scale aGVHD patients are needed to clarify whether the impaired BM EPCs directly affect haematopoiesis or act through their immunoregulatory effects in aGVHD-associated cytopenia. ROS are free radicals derived from diatomic oxygen and exhibit diverse reactivities (Eliades et al, 2012; Ludin et al, 2014; Kong et al, 2016b) . Intracellular ROS homeostasis is essential for maintenance of HSC quiescence and self-renewal (Eliades et al, 2012) . Our recent study suggested that ROS help maintain the function of HSCs and EPCs in patients with PGF after allo-HSCT (Kong et al, 2016b) . The current study indicates that the impairment of EPCs was associated with elevated intracellular ROS levels in aGVHD patients. Therefore, it would be interesting and informative to investigate the efficacy of therapeutic strategies, such as Nacetyl-L-cysteine (a reactive oxygen species scavenger) (Kong et al, 2016b (Kong et al, , 2018b Shi et al, 2016) , to improve the prognosis of GVHD-associated cytopenia patients by enhancing BM EPCs.
In summary, the current study demonstrated for the first time that reduced and dysfunctional BM EPCs may be involved in the pathogenesis of aGVHD. Moreover, the severity of aGVHD or GVHD-mediated cytopenia was associated with impairment of BM EPCs in aGVHD patients. Although further validation with large-scale aGVHD patients is required, our data indicate that improvement of BM EPCs may represent a potential therapeutic approach, especially in GVHD-associated cytopenia patients, after allo-HSCT.
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